Title |
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
|
---|---|
Published in |
Frontiers in oncology, July 2018
|
DOI | 10.3389/fonc.2018.00262 |
Pubmed ID | |
Authors |
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss, on behalf of the ABOUND.70+ Investigators, Ajeet Gajra, Andrei Dobrescu, Bohdan E. Halibey, Corey Langer, Daniel Haggstrom, David A. Smith, Eric Anderson, Eugene H. Paschold, Haiying Cheng, Haythem Ali, Hossein Borghaei, Jared Weiss, Jawad Elias Francis, Ayla Ahmed Kessler, Jen C. Wang, Jonathan Wade Goldman, Jose E. Najera, Nadim F. Nimeh, Joseph Rosales, Kartik Konduri, Konstantin H. Dragnev, Leonardo Forero, Lynne A. Bui, Marc R. Matrana, Matei P. Socoteanu, Maurice Willis, Monika Joshi, Morton Coleman, Moses Sundar Raj, Navkiranjit Gill, Patricia M. Plezia, Manuel R. Modiano, R. Timothy Webb, Rita Axelrod, Robert Andrew Dichmann, Robert M. Jotte, Ronald P. Harris, Scott Anthony Sonnier, Vijay Patel, Shaker R. Dakhil, Tarek Mekhail, Thomas Hensing, Tony M. Samaha, Vicky Lee, Kimberly McGregor, William Eyre Lawler, William L. Skinner, William T. DeRosa |
Abstract |
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab-paclitaxel days 1, 8, 15 plus carboplatin day 1 of a 21-day cycle (21d) or the same nab-paclitaxel/carboplatin regimen with a 1-week break between cycles (21d + break; 28d). The primary endpoint was the percentage of patients with grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression. Other key endpoints included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). A total of 143 patients were randomized (71 to 21d, 72 to 21d + break). The percentage of patients with grade ≥ 2 PN or grade ≥ 3 myelosuppression was similar between the 21d and 21d + break arms (76.5 and 77.1%; P = 0.9258). Treatment exposure was lower in the 21d arm compared with the 21d + break arm. Median OS was 15.2 and 16.2 months [hazard ratio (HR) 0.72, 95% CI 0.44-1.19; P = 0.1966], median PFS was 3.6 and 7.0 months (HR 0.48, 95% CI 0.30-0.76; P < 0.0019), and ORR was 23.9 and 40.3% (risk ratio 1.68, 95% CI 1.02-2.78; P = 0.0376) in the 21d and 21d + break arms, respectively. In summary, the 1-week break between treatment cycles significantly improved PFS and ORR but did not significantly reduce the percentage of grade ≥ 2 PN or grade ≥ 3 myelosuppression. Overall, the findings support the results of prior subset analyses on the safety and efficacy of first-line nab-paclitaxel/carboplatin in elderly patients with advanced NSCLC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 75% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Members of the public | 2 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 15% |
Other | 1 | 8% |
Lecturer | 1 | 8% |
Student > Ph. D. Student | 1 | 8% |
Student > Bachelor | 1 | 8% |
Other | 2 | 15% |
Unknown | 5 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 31% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 15% |
Psychology | 1 | 8% |
Nursing and Health Professions | 1 | 8% |
Unknown | 5 | 38% |